TerminatedPhase 1NCT00430443

Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Callisto Pharmaceuticals
Principal Investigator
Gary Jacob, Ph.D.
Callisto Pharmaceuticals, Inc.
Intervention
Liposomal Annamycin(drug)
Enrollment
3 enrolled
Eligibility
21 years · All sexes
Timeline
20072009

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00430443 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials